Compare YUMC & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YUMC | ILMN |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3B | 20.4B |
| IPO Year | 2016 | 2000 |
| Metric | YUMC | ILMN |
|---|---|---|
| Price | $52.46 | $115.47 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $124.24 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | 7.73 | ★ 170.87 |
| EPS | 2.51 | ★ 5.45 |
| Revenue | ★ $11,797,000,000.00 | $4,343,000,000.00 |
| Revenue This Year | $9.42 | $6.52 |
| Revenue Next Year | $5.93 | $5.49 |
| P/E Ratio | ★ $21.10 | $22.26 |
| Revenue Growth | ★ 4.37 | N/A |
| 52 Week Low | $41.00 | $68.70 |
| 52 Week High | $58.39 | $155.53 |
| Indicator | YUMC | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 34.71 |
| Support Level | $43.02 | $114.88 |
| Resistance Level | $56.51 | $135.68 |
| Average True Range (ATR) | 1.12 | 4.50 |
| MACD | -0.41 | -0.21 |
| Stochastic Oscillator | 27.48 | 1.62 |
Yum China is the largest restaurant operator in China, with over 18,000 locations and USD 12 billion in systemwide sales as of 2025. It generates revenue primarily from its own restaurants and franchise fees. While KFC and Pizza Hut are its flagship brands, Yum China's portfolio also includes Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza. As a trademark licensee of Yum Brands, Yum China pays 3% of KFC and Pizza Hut's systemwide sales to its former parent, from which it spun off in 2016. However, even before the separation, Yum China was granted substantial autonomy, giving its Chinese leadership decision-making authority over menu, supply chain, and marketing—an unusual practice for Western chains at the time.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.